Dr Alfredo Addeo (University Hospital of Geneva, Geneva, Switzerland), Prof Nicolas Girard (Institut Curie, Paris, France) and Prof Natasha Leighl (Princess Margaret Cancer Centre, Toronto, Canada) discuss the recent advances in the treatment of patients with exon 20 insertion-positive NSCLC.

The panel evaluates the use of new and emerging therapeutic options for EGFR exon 20 insertion mutations in clinical practice, and talks about the unmet needs in the management of EGFR+ NSCLC.

Prof Girard analyses the real-world treatment outcomes of amivantamab in pre-approval access participants with advanced non-small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations (ex20ins).

He also talks about the indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR ex20ins+ NSCLC.

Prof Leighl discusses the studies regarding EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC from the German prospective, CRISP registry real-world cohort (AIO-TRK-0315).

She also talks about the clinical characteristics, treatment patterns, and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients. Dr Addeo concludes by discussing the future of the treatment of EGFR+ exon 20 ins mutant NSCLC.